Biotechnology company Panacea Biotec announced Q1FY25 results: Panacea Biotec and ICMR Announce Phase III Clinical Trials for Tetravalent Dengue Vaccine, DengiALL On the occasion of India's 78th Independence Day, Panacea Biotec Limited and the Indian Council of Medical Research (ICMR) are proud to announce the commencement of Phase III clinical trials for the tetravalent dengue candidate vaccine, DengiALL. The trials, approved by the Drugs Controller General of India (DCGI), will be conducted across 19 sites in India, involving 10,335 participants. The journey of DengiALL began in 2006 at Panacea Biotec with the licensing and transfer of novel attenuated tetravalent dengue virus strains from the National Institutes of Health, USA. Phase I/II clinical trials were successfully conducted in the Indian population, with a comprehensive three-year safety follow-up completed in 2020. In March 2022, Panacea Biotec and ICMR signed an MoU to collaborate on Phase III clinical trials in India. On the occasion, Dr. Rajesh Jain, Chairman and Managing Director, at Panacea Biotec, said “DengiALL vaccine development has a long way since it was initiated in 2006 in collaboration with the National Institute of Health USA. We are excited to announce that our dengue vaccine candidate has successfully entered the penultimate Phase 3 clinical trials in India in collaboration with the Indian Council of Medical Research. This milestone brings us one step closer to providing a safe and effective solution for preventing dengue fever, a disease that poses a significant public health challenge. We are committed to ensuring that this vaccine meets the highest standards of safety and efficacy, and we are optimistic about its potential to make a meaningful impact on the lives of millions.” Result PDF